Clinical trial · Interventional
ZD6474 Phase IIa Dose Finding Multicentre Study
A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]
NCT00252746CI-TRIAL-00023640completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ZD6474 (vandetanib) 100mg | Drug | Vandetanib | ALIAS |
| ZD6474 (vandetanib) 200mg | Drug | Vandetanib | ALIAS |
| ZD6474 (vandetanib) 300mg | Drug | Vandetanib | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- ZD6474 100mg
- description
- Daily dose
- interventionNames
- Drug: ZD6474 (vandetanib) 100mg
- type
- EXPERIMENTAL
- label
- ZD6474 200mg
- description
- daily dose
- interventionNames
- Drug: ZD6474 (vandetanib) 200mg
- type
- EXPERIMENTAL
- label
- ZD6474 300mg
- description
- daily dose
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of written informed consent. * Life expectancy of 12 weeks or longer. Exclusion Criteria: * Pregnancy, breast feeding or female patients wishing to become pregnant. * Treatment with a non-approved or investigational drug within 30 days before enrolment
References
Publications (1)
- BACKGROUNDKiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2008 Apr;3(4):386-93. doi: 10.1097/JTO.0b013e318168d228. PMID 18379357